Clinical Trial

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-17.
Trial Details
NCT Number NCT07184385
Lead Sponsor StemCyte, Inc.
Conditions Long COVID, Post-COVID-19 Condition, Post-COVID Syndrome, Post-COVID Condition
Enrollment 60 participants
Start Date 2026-03-31
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-23